Should You Buy BioRestorative Therapies Inc (BRTX) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
1.140
1 Day change
52 Week Range
2.510
Analysis Updated At
2026/01/28
BRTX is not a good buy right now for a beginner long-term investor with $50k–$100k. The chart trend is bearish, there are no proprietary buy signals today, and the latest reported quarter shows a severe revenue collapse with weak margins and ongoing losses. With no near-term catalysts or supportive sentiment signals, the risk/reward does not favor an impatient long-term entry at this time.
Technical Analysis
Trend/structure: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), implying sustained downside trend across long-, mid-, and short-term horizons.
Momentum: MACD histogram is negative (-0.0056) and expanding lower, suggesting downside momentum is strengthening.
RSI: RSI_6 = 31.82 (near oversold but still labeled neutral here). This can precede bounces, but it is not a buy signal by itself while trend/momentum remain bearish.
Key levels: Pivot 1.13 (price 1.11 is below pivot = weak). Support S1 1.081 then S2 1.05. Resistance R1 1.18 then R2 1.21.
Pattern-based forward bias (similar candlesticks): Higher probability skew to declines (-1.33% next day / -3.56% next week / -6.37% next month).
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Positive Catalysts
and RSI is near oversold, which can sometimes support a short-term bounce—but this is not confirmed by trend signals.
Neutral/Negative Catalysts
Clear bearish technical setup (negative MA stack and weakening MACD). Pattern-based outlook points to continued downside over the next day/week/month. Fundamentals show a major revenue and margin deterioration in the latest quarter, with losses continuing. No recent supportive news flow, and no notable hedge fund/insider accumulation signals (both described as neutral).
Financial Performance
Latest quarter: 2025/Q3. Revenue fell to 11,800, down -94.95% YoY, indicating a sharp contraction in business activity. Gross margin dropped to 10.42 (down -88.70% YoY), showing significantly weaker profitability on sales. Net income improved YoY to -3,038,277 (still a loss), and EPS improved to -0.33 (still negative). Overall: improving loss metrics off a weak base, but the top-line collapse and margin compression are strongly negative for long-term confidence.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target data provided, so there is no observable Wall Street trend in upgrades/downgrades or target revisions. Pros/cons from available data: Pros—possible short-term technical mean-reversion near support; Cons—bearish trend, no proprietary buy signals, severe YoY revenue decline, weak margins, and continued losses.
Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is 8 USD with a low forecast of 8 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is 8 USD with a low forecast of 8 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
